Correspondence 0001493152-22-035787 from OKYO Pharma Ltd (OKYO) (CIK 0001849296) (OKYO)
OKYO Pharma Ltd (OKYO) (CIK 0001849296)
Date: Dec. 16, 2022 · CIK: 0001849296 · Accession: 0001493152-22-035787
AI Filing Summary & Sentiment
File numbers found in text: 333-268675
Letter
December 16, 2022
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, NE
Washington, D.C. 20549
Attn:
Tyler Howes
Re: OKYO Pharma LTD (the “Company”)
Registration Statement on Form F-1/A
File No. 333-268675
Acceleration Request
Requested Date: December 20, 2022
Requested Time: 5:00 p.m., Eastern Standard Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), ThinkEquity LLC, as representative of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form F-1/A (File No. 333-268675) (the “Registration Statement”) to become effective on Tuesday, December 20, 2022, at 5:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
[Signature Page Follows]
Securities and Exchange Commission, p. 2
December 16, 2022
Very truly yours,
ThinkEquity LLC
Show Raw Text
CORRESP
1
filename1.htm
December
16, 2022
Via
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, NE
Washington, D.C. 20549
Attn:
Tyler
Howes
Re:
OKYO Pharma LTD (the “Company”)
Registration Statement on Form F-1/A
File
No. 333-268675
Acceleration Request
Requested
Date: December 20, 2022
Requested
Time: 5:00 p.m., Eastern Standard Time
Ladies
and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), ThinkEquity LLC, as representative
of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the Registration Statement on Form F-1/A (File No. 333-268675) (the “Registration Statement”)
to become effective on Tuesday, December 20, 2022, at 5:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.
Pursuant
to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus,
to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We
have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities
Exchange Act of 1934, as amended, to the extent applicable.
[Signature
Page Follows]
Securities
and Exchange Commission, p. 2
December
16, 2022
Very truly yours,
ThinkEquity LLC
By:
/s/
Priyanka Mahajan
Name:
Priyanka
Mahajan
Title:
Managing
Director, Investment Banking
cc:
Gary
Jacob, OKYO Pharma Ltd
Jeffrey
Fessler, Sheppard, Mullin, Richter & Hampton LLP
Anthony
Marsico, Dorsey & Whitney LLP